How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Epidural Syringes Market
- By Product Type: Standard Epidural Syringes, Safety Epidural Syringes, Combined Spinal-Epidural (CSE) Syringes, Pediatric Epidural Syringes, Pre-filled Epidural Syringes
- By Material: Plastic Epidural Syringes, Glass Epidural Syringes, Stainless Steel Epidural Syringes
- By Application: Anesthesia, Pain Management, Obstetrics, Surgical Procedures
- By End User: Hospitals, Ambulatory Surgical Centers, Clinics, Specialty Pain Management Centers
- By Needle Type: Standard Epidural Needles, Tuohy Needles, Pencil Point Needles, Hustead Needles
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Standard Epidural Syringes leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.177 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.185 →
Full report · locked preview
Everything inside the Epidural Syringes Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Material 3
Application 4
End User 4
Needle Type 4
Companies profiled
Becton Dickinson and Company (BD)
Smiths Medical
Teleflex Incorporated
Fresenius Kabi
B. Braun Melsungen AG
Nipro Corporation
Terumo Corporation
Halyard Health (now part of Owens & Minor)
Vygon SA
SteriMax Inc.
Noble Medical Group
Unimed S.A.
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Becton Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Smiths Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Teleflex Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Fresenius Kabi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Nipro Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Terumo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Halyard Health (now part of Owens & Minor)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Vygon SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →SteriMax Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Noble Medical Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Unimed S.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Medline Industries Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Cardinal Health
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,825M by 2033 · 3.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Standard Epidural Syringes56.8
- Safety Epidural Syringes8.5
- Combined Spinal-Epidural (CSE) Syringes16.1
- Pediatric Epidural Syringes7.5
- Pre-filled Epidural Syringes11.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,434M → $2,073M · 4.7%
Europe$999.7M → $1,424M · 4.5%
Asia Pacific$912.8M → $1,092M · 2.3%
Latin America$565.1M → $844.0M · 5.1%
Middle East and Africa$434.7M → $549.0M · 3.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.682026
3.692027
3.702028
3.722029
3.722030
3.742031
3.752032
3.762033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Becton Dickinson and Company (BD)23.0
- Smiths Medical14.3
- Teleflex Incorporated11.5
- Fresenius Kabi4.3
- B. Braun Melsungen AG5.8
- Nipro Corporation13.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type24.0%
Material14.5%
Application16.7%
End User22.4%
Needle Type22.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe23.8
- Asia Pacific18.3
- Latin America14.1
- Middle East and Africa9.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Becton Dickinson and Company (BD) | 83 | 83 | 83 | 83 | 88 | 92 | 85 |
| Smiths Medical | 85 | 90 | 80 | 88 | 76 | 84 | 84 |
| Teleflex Incorporated | 66 | 68 | 69 | 73 | 84 | 84 | 74 |
| Fresenius Kabi | 69 | 73 | 74 | 78 | 79 | 71 | 74 |
| B. Braun Melsungen AG | 71 | 59 | 67 | 69 | 74 | 70 | 68 |
| Nipro Corporation | 71 | 46 | 53 | 53 | 53 | 54 | 55 |
| Terumo Corporation | 64 | 46 | 61 | 48 | 51 | 49 | 53 |
| Halyard Health (now part of Owens & Minor) | 36 | 42 | 42 | 47 | 43 | 51 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Becton Dickinson and Company (BD)
- Smiths Medical
- Teleflex Incorporated
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Becton Dickinson and Company (BD) | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Smiths Medical | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Teleflex Incorporated | − | − | − | ✓ | ◐ | ◐ |
| Fresenius Kabi | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| B. Braun Melsungen AG | ◐ | − | ◐ | ◐ | − | − |
| Nipro Corporation | ◐ | − | ◐ | ◐ | − | ◐ |
| Terumo Corporation | − | − | − | − | − | − |
| Halyard Health (now part of Owens & Minor) | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Becton Dickinson and Company (BD)85
2Smiths Medical84
3Teleflex Incorporated74
4Fresenius Kabi74
5B. Braun Melsungen AG68
6Nipro Corporation55
7Terumo Corporation53
8Halyard Health (now part of Owens & Minor)44
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Becton Dickinson and Company (BD)Smiths Medical
Challenger3
Strong scale, closing on the leaders.
Teleflex IncorporatedFresenius KabiB. Braun Melsungen AG
Niche3
Specialists in a single segment or region.
Nipro CorporationTerumo CorporationHalyard Health (now part of Owens & Minor)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Epidural Syringes Market — a $136M beachhead inside a $2.34B market.
Beachhead (SOM)$136Mobtainable near-term
Serviceable (SAM)$818Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Standard Epidural Syringes
Best fit — highest urgency & budget in Product Type.
Economic buyer76 fit
Safety Epidural Syringes
Strong fit — clear ROI and a fast path to value.
End user68 fit
Combined Spinal-Epidural (CSE) Syringes
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Material & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel29%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Epidural Syringes Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified23%
Evaluation14%
Closed-won7%
$18.6KCAC
$88KLTV
4.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Epidural Syringes Market is a high-growth opportunity — $10.2B by 2033, compounding at 10.7%.
TAM · 2025$4.53Btoday
TAM · 2033$10.2Bforecast
CAGR10.7%2027–2033
Cumulative$63.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.2BTotal addressable market
SAM$3.55BServiceable available market
SOM$738MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.7% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.2BLarge & growingTAM by 2033 at 10.7% CAGR
$3.55BServiceable nowreachable with today’s model
$738MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.95BBear6.9% CAGR
$10.2BBase10.7% CAGR
$13.1BBull14.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Material optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Epidural Syringes Market — a $7.74B market by 2033. Plan: grow share from 7.6% to 13.7%.
Market size · 2033$7.74Btotal addressable
Market CAGR9.5%2027–2033
Target share13.7%from 7.6% today
Revenue ambition$1.06Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.6% | 13.7% | At risk |
| Revenue | $639M | $1.06B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 30.2% | 40.0% | At risk |
| Customer retention | 88.4% | 95.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Material capability
A defensible second engine — invest in Material to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Material
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $146M capacity & capability investment
- Greenlight bolt-on M&A in Material
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Epidural Syringes Market conversation — a $1.23B market you can size, segment and defend in minutes.
Market size · 2033$1.23Btotal opportunity
Growth11.3%CAGR to 2033
Addressable buyers1,290+accounts in scope
Typical ROI5.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.1×return on cost, year one
< 4 mopayback period
$52K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Becton Dickinson and Company (BD)Smiths MedicalTeleflex IncorporatedFresenius KabiB. Braun Melsungen AGNipro CorporationTerumo CorporationHalyard Health (now part of Owens & Minor)+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Epidural Syringes Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Epidural Syringes Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Epidural Sensor Market
Market size, share, segmentation and regional forecast.
$394M market · 2025 base year
View reportEpidural Needles Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportMedical Stopcocks Market
Market size, share, segmentation and regional forecast.
$806M market · 2025 base year
View reportEpidural-flat Filter Market
Market size, share, segmentation and regional forecast.
$946M market · 2025 base year
View reportEpidural Catheter Connector Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportCarotid Ttenosis Drugs Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportEpidiolex Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportEpidermal Sensors Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportEpidermal Growth Factor Receptor (EGFR) ELISA Kit Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportEpidermal Growth Factor Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportEpidermal Growth Factor (EGF) Antibody Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportEpidermal Electronic Devices Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.